Business
Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on May 28, 2025, at 2:30 PM ET.
About this update from Whitehawk Therapeutics, Inc.
[{"type":"text","content":"MORRISTOWN, N.J., May 21, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on May 28, 2025, at 2:30 PM ET.","length":467,"tagName":"p"},{"type":"text","content":"A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.","length":191,"tagName":"p"},{"type":"text","content":"About Whitehawk Therapeutics ","length":28,"tagName":"p"},{"type":"text","content":"Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.","length":593,"tagName":"p"},{"type":"text","content":"Contact:[email protected]","length":27,"tagName":"p"},{"type":"image","alt":"Whitehawk Therapeutics, Inc. logo (PRNewsfoto/Whitehawk Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Whitehawk Therapeutics, Inc. logo (PRNewsfoto/Whitehawk Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":83,"url":"https://media.zenfs.com/en/prnewswire.com/bc5017aa21c2d27c4ec68be1c82a7c84"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BvJZhr8bfe41tWjO7_6U4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/bc5017aa21c2d27c4ec68be1c82a7c84","width":400,"height":83}},"href":"https://mma.prnewswire.com/media/2644441/Whitehawk_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"image","alt":"Cision","displaySize":"","headline":null,"...